A Phase 4 interventional study of Metformin IR and Metformin XR in Diabetes Mellitus, Type 2, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Germany. Open to participants aged 18 Years to 79 Years. Per ClinicalTrials.gov, last updated 2017-01-24.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 293 studies testing metformin in Diabetes Mellitus, Type 2 — 17 open to participants now, 22 under way, 2 of them phase 3. Metformin · Diabetes Mellitus, Type 2.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, this one is the 40th largest by enrollment of the 287 interventional ones that give a count, is one of 16 that started in 2014, is one of 98 in phase 4, and was the 195th registered.
10,396 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →17 of the 293 studies testing metformin in Diabetes Mellitus, Type 2 are open now, in 7 countries. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18–75 · Men only
JW Pharmaceutical · Sites in Korea, Republic of
Ages 19+
University of California, San Francisco · Sites in United States
Ages 10–21 · Healthy volunteers
RenJi Hospital · Sites in China
Ages 18–65
Lille Catholic University · Sites in France
Ages 18–40
By country, each count listing its studies:
Metformin: first FDA approval 1995 (GLUCOPHAGE), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 18 Years to 79 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
293 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 58 · Phase 2 31 · Phase 3 77 · Phase 4 98
First in 1996; this study’s year is marked. 16 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 532 is above the median of 80 across 8,367 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 100 across the 287 interventional studies. Of the 235 that completed or were terminated, 89 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
155 of 293 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 5 studies filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
7 of the studies testing metformin in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02087826Massachusetts General HospitalStudy of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS | 2026-12 |
| NCT06120881University of California, San FranciscoPrecision Dosing of Metformin in Youth With T2D | 2026-12-31 |
| NCT02969798The University of Texas Health Science Center at San AntonioPre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT) | 2027-02-28 |
| NCT07442006JW PharmaceuticalGlycemic Variability of Combination Therapies in T2DM | 2027-03-31 |
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 293 studies testing metformin in Diabetes Mellitus, Type 2, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a Phase 4, prospective, open label, randomized, parallel controlled multicenter trial in which metformin extended release (XR) will be compared with metformin immediate release (IR) for the gastrointestinal tolerability and efficacy in the newly diagnosed subjects with Type 2 diabetes who have glycosylated hemoglobin (HbA1c) value between 7.0 to 10.0 percent (%).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Metformin IR
Drug: Metformin XR
Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
Also known as: Glucophage IR
Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
Also known as: Glucophage XR
Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16
Time frame: Baseline, Week 16
Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period
An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.
Time frame: Baseline up to Week 16
Percentage of Subjects With Pre-specified Gastrointestinal Adverse Events During Treatment Period
An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Number of subjects with pre-specified gastrointestinal adverse events (diarrhea, nausea, abdominal pain, bloating, constipation, dyspepsia and flatulence) were reported.
Time frame: Baseline up to Week 16
Change From Baseline in Fasting Plasma Glucose (FPG) Level at Week 1, 2, 4, 8, 12 and 16
Time frame: Baseline, Week 1, 2, 4, 8, 12,16
Change From Baseline in 2-Hour Postprandial Plasma Glucose (PPG) Level at Weeks 8 and 16
The 2-hour Postprandial plasma glucose (PPG) level refers to the plasma glucose concentrations after 2 hours of eating.
Time frame: Baseline, Week 8 and 16
Percentage of Subjects With Hypoglycemia
Hypoglycemia, also called as low blood glucose or low blood sugar, is defined as the blood glucose level of less than normal (that is less than 3.9 millimole per liter \[mmol/L\]).
Time frame: Baseline up to Week 16
Percentage of Subjects With Marked Hyperglycemia
Marked hyperglycemia was defined as the FPG level of greater than or equal to 11.1 mmol/L.
Time frame: Baseline up to Week 16
Percentage of Subjects With HbA1c Less Than (<) 7%
Time frame: Baseline up to Week 16
Percentage of Subjects Who Are Totally Intolerant to the Treatment
Subjects were considered to be totally intolerant if they experienced a Grade 3 or higher toxicity considered at least possibly related to the treatment.
Time frame: Baseline up to Week 16
Percentage of Subjects With HbA1c Less Than (<) 7% and With no Severe Gastrointestinal (GI) and Other Adverse Events (AEs)
Percentage of subjects with HbA1c \<7% and with no severe GI and other AEs were reported. Severe adverse events were based on Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 and were defined as those events which were medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL). Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
Time frame: Baseline up to Week 16
Percentage of Subjects Who Are Compliant to Treatment
Compliance was defined as not skipping or forgetting dosing or not delaying the dosing time. Subjects who never missed a dose of medication were considered compliant.
Time frame: Baseline up to Week 16
| Milestone | Metformin IR | Metformin XR |
|---|---|---|
| Started | 267 | 265 |
| Safety population | 261 | 264 |
| Completed | 227 | 222 |
| Not completed | 40 | 43 |
| Withdrew: Adverse event | 9 | 14 |
| Withdrew: Lost to follow-up | 16 | 8 |
| Withdrew: Protocol violation | 4 | 5 |
| Withdrew: Lack of efficacy | 0 | 2 |
| Withdrew: Withdrawal by subject | 7 | 9 |
| Withdrew: Other | 4 | 5 |
| Percentage of HbA1c | Metformin IR | Metformin XR |
|---|---|---|
| Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 16 | -1.61 ± 0.05 | -1.58 ± 0.05 |
An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product.
| percentage of subjects | Metformin IR | Metformin XR |
|---|---|---|
| Overall Gastrointestinal (GI) Tolerability Assessed as Percentage of Subjects With Gastrointestinal Adverse Events During Treatment Period | 23.8 (18.72 to 29.39) | 22.3 (17.47 to 27.86) |
An adverse event (AE) was defined as any untoward medical occurrence in a subject which does not necessarily have a causal relationship with the treatment. An AE was any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with use of a medicinal product, whether or not considered related to the medicinal product. Number of subjects with pre-specified gastrointestinal adverse events (diarrhea, nausea, abdominal pain, bloating, constipation, dyspepsia and flatulence) were reported.
| percentage of subjects | Metformin IR | Metformin XR |
|---|---|---|
| Diarrhoea | 16.5 (12.19 to 21.54) | 12.5 (8.76 to 17.10) |
| Abdominal Distension | 6.1 (3.54 to 9.76) | 6.4 (3.80 to 10.11) |
| Nausea | 6.1 (3.54 to 9.76) | 4.5 (2.37 to 7.81) |
| Abdominal Pain | 2.3 (0.85 to 4.94) | 1.9 (0.62 to 4.36) |
| Constipation | 1.9 (0.62 to 4.41) | 1.9 (0.62 to 4.36) |
| Dyspepsia | 1.1 (0.24 to 3.32) | 0.8 (0.09 to 2.71) |
| Flatulence | 0.4 (0.01 to 2.12) | 0 (0.00 to 1.39) |
| Millimole Per Liter (mmol/L) | Metformin IR | Metformin XR |
|---|---|---|
| Baseline (n=251, 254) | 8.464 ± 1.7470 | 8.690 ± 2.0977 |
| Change at Week 1 (n= 249, 248) | -0.647 ± 1.5615 | -0.736 ± 1.4305 |
| Change at Week 2 (n= 243, 244) | -1.324 ± 1.4426 | -1.267 ± 1.9346 |
| Change at Week 4 (n= 240, 239) | -1.558 ± 1.6245 | -1.604 ± 1.7971 |
| Change at Week 8 (n= 219, 230) | -2.075 ± 1.7359 | -1.999 ± 2.0192 |
| Change at Week 12 (n= 216, 221) | -2.053 ± 1.7599 | -2.048 ± 1.8532 |
| Change at Week 16 (n= 214, 218) | -1.976 ± 1.7529 | -2.183 ± 1.8481 |
The 2-hour Postprandial plasma glucose (PPG) level refers to the plasma glucose concentrations after 2 hours of eating.
| mmol/L | Metformin IR | Metformin XR |
|---|---|---|
| Baseline (n= 223, 231) | 14.604 ± 3.4334 | 14.764 ± 3.7705 |
| Change at Week 8 (n= 215, 229) | -3.608 ± 3.6964 | -3.264 ± 5.9134 |
| Change at Week 16 (n= 213, 215) | -3.642 ± 3.7261 | -3.693 ± 3.5414 |
Hypoglycemia, also called as low blood glucose or low blood sugar, is defined as the blood glucose level of less than normal (that is less than 3.9 millimole per liter \[mmol/L\]).
| percentage of subjects | Metformin IR | Metformin XR |
|---|---|---|
| Percentage of Subjects With Hypoglycemia | 1.1 (0.24 to 3.32) | 3.0 (1.32 to 5.88) |
Marked hyperglycemia was defined as the FPG level of greater than or equal to 11.1 mmol/L.
| percentage of subjects | Metformin IR | Metformin XR |
|---|---|---|
| Percentage of Subjects With Marked Hyperglycemia | 0.7 (0.09 to 2.68) | 2.3 (0.84 to 4.86) |
| percentage of subjects | Metformin IR | Metformin XR |
|---|---|---|
| Percentage of Subjects With HbA1c Less Than (<) 7% | 68.5 (62.60 to 74.06) | 69.8 (63.90 to 75.28) |
Subjects were considered to be totally intolerant if they experienced a Grade 3 or higher toxicity considered at least possibly related to the treatment.
| percentage of subjects | Metformin IR | Metformin XR |
|---|---|---|
| Percentage of Subjects Who Are Totally Intolerant to the Treatment | 7.3 (4.44 to 11.13) | 5.7 (3.21 to 9.20) |
Percentage of subjects with HbA1c \<7% and with no severe GI and other AEs were reported. Severe adverse events were based on Common Terminology Criteria for Adverse Events (CTCAE), version 4.0 and were defined as those events which were medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily living (ADL). Self-care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
| percentage of subjects | Metformin IR | Metformin XR |
|---|---|---|
| Percentage of Subjects With HbA1c Less Than (<) 7% and With no Severe Gastrointestinal (GI) and Other Adverse Events (AEs) | 68.2 (62.21 to 73.71) | 69.8 (63.90 to 75.28) |
Compliance was defined as not skipping or forgetting dosing or not delaying the dosing time. Subjects who never missed a dose of medication were considered compliant.
| percentage of subjects | Metformin IR | Metformin XR |
|---|---|---|
| Percentage of Subjects Who Are Compliant to Treatment | 99.2 | 99.2 |
Collected over Baseline up to Week 18. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Metformin IR | — | 6/249 (2.4%) | 96/249 (38.6%) |
| Metformin XR | — | 2/264 (0.8%) | 136/264 (51.5%) |
| Metformin IR to XR | — | 0/12 (0%) | 12/12 (100%) |
| Event | Metformin IR | Metformin XR | Metformin IR to XR |
|---|---|---|---|
| Cardiac failure chronicCardiac disorders | 1/249 | 0/264 | 0/12 |
| Retinal detachmentEye disorders | 1/249 | 0/264 | 0/12 |
| Liver injuryHepatobiliary disorders | 1/249 | 0/264 | 0/12 |
| Foot fractureInjury, poisoning and procedural complications | 1/249 | 0/264 | 0/12 |
| Adrenal adenomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/249 | 0/264 | 0/12 |
| Haemangioma of liverNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/249 | 0/264 | 0/12 |
| Blood glucose increasedInvestigations | 0/249 | 1/264 | 0/12 |
| Blood ketone body increasedInvestigations | 0/249 | 1/264 | 0/12 |
| Brain neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/249 | 1/264 | 0/12 |
| Event | Metformin IR | Metformin XR | Metformin IR to XR |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 34/249 | 33/264 | 9/12 |
| NauseaGastrointestinal disorders | 14/249 | 12/264 | 3/12 |
| Muscular WeaknessMusculoskeletal and connective tissue disorders | 1/249 | 1/264 | 3/12 |
| Abdominal PainGastrointestinal disorders | 5/249 | 5/264 | 1/12 |
| Abdominal Pain UpperGastrointestinal disorders | 6/249 | 9/264 | 1/12 |
| Abnormal FaecesGastrointestinal disorders | 0/249 | 3/264 | 1/12 |
| DyspepsiaGastrointestinal disorders | 2/249 | 2/264 | 1/12 |
| Urinary tract InfectionInfections and infestations | 3/249 | 9/264 | 1/12 |
| Muscle InjuryInjury, poisoning and procedural complications | 0/249 | 0/264 | 1/12 |
| Blood pressure DecreasedInvestigations | 0/249 | 0/264 | 1/12 |
Intent to Treat (ITT) population included all subjects who were randomly allocated to a treatment based on the intention to treat
| Age, Continuous(years) | Metformin IR | Metformin XR | Total |
|---|---|---|---|
| Mean | 54.4 ± 10.21 | 53.1 ± 9.72 | 53.8 ± 9.98 |
| Gender(Participants) | Metformin IR | Metformin XR | Total |
|---|---|---|---|
| Female | 112 | 108 | 220 |
| Male | 155 | 157 | 312 |
The record gives a start of Dec 2014, a primary completion of Nov 2015 and a completion of Apr 2016. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Metformin
Merck KGaA, Darmstadt, Germany →